William Blair Issues Positive Forecast for AUTL Earnings

Key Points

• William Blair analysts have raised their Q3 2025 EPS estimate for Autolus Therapeutics from ($0.23) to ($0.21), with a full-year earnings estimate of ($0.94) per share.
• Wells Fargo decreased its price target on Autolus Therapeutics from $6.00 to $5.00, while Needham & Company maintains a "buy" rating with a price target of $10.00.
• The company's recent earnings report showed a beat at ($0.18) EPS, surpassing the consensus estimate of ($0.24), with revenues of $13.50 million exceeding expectations of $12.92 million.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) - Analysts at William Blair increased their Q3 2025 earnings estimates for shares of Autolus Therapeutics in a research report issued to clients and investors on Tuesday, August 12th. William Blair analyst M. Phipps now anticipates that the company will earn ($0.21) per share for the quarter, up from their previous forecast of ($0.23). The consensus estimate for Autolus Therapeutics' current full-year earnings is ($0.94) per share. William Blair also issued estimates for Autolus Therapeutics' Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.87) EPS, Q1 2026 earnings at ($0.21) EPS, Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.85) EPS, FY2027 earnings at ($0.70) EPS and FY2028 earnings at ($0.37) EPS.

A number of other research analysts have also weighed in on AUTL. Wells Fargo & Company decreased their price target on shares of Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 13th. Wall Street Zen upgraded shares of Autolus Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. Finally, Needham & Company LLC restated a "buy" rating and set a $10.00 price target on shares of Autolus Therapeutics in a report on Monday, July 21st. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, Autolus Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $9.12.

Autolus Therapeutics Stock Down 3.4%

Shares of AUTL stock traded down $0.06 during mid-day trading on Friday, hitting $1.73. 2,410,336 shares of the stock were exchanged, compared to its average volume of 1,886,458. The firm has a fifty day moving average of $2.30 and a 200 day moving average of $1.89. Autolus Therapeutics has a 52-week low of $1.1050 and a 52-week high of $5.00. The company has a market cap of $460.42 million, a PE ratio of -2.06 and a beta of 1.90.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.06. The firm had revenue of $13.50 million for the quarter, compared to analysts' expectations of $12.92 million.

Institutional Trading of Autolus Therapeutics

Several institutional investors have recently added to or reduced their stakes in AUTL. Legal & General Group Plc increased its holdings in Autolus Therapeutics by 392.0% in the 4th quarter. Legal & General Group Plc now owns 297,736 shares of the company's stock valued at $697,000 after purchasing an additional 237,224 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Autolus Therapeutics by 146.7% in the fourth quarter. Renaissance Technologies LLC now owns 618,942 shares of the company's stock worth $1,455,000 after acquiring an additional 368,071 shares in the last quarter. Barclays PLC grew its stake in shares of Autolus Therapeutics by 1,094.3% in the fourth quarter. Barclays PLC now owns 11,859 shares of the company's stock worth $28,000 after acquiring an additional 10,866 shares in the last quarter. Jump Financial LLC acquired a new position in shares of Autolus Therapeutics in the fourth quarter worth $170,000. Finally, Virtus ETF Advisers LLC grew its stake in shares of Autolus Therapeutics by 29.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company's stock worth $62,000 after acquiring an additional 6,081 shares in the last quarter. Institutional investors and hedge funds own 72.83% of the company's stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.